Biotech7 months ago
Grifols Announces Positive Results from Fanhdi Phase IV Study
Grifols reports positive results from its Phase IV study of Fanhdi for von Willebrand disease (VWD) treatment, showing safety and efficacy. Presented at the 2024 World...